Dr. David Dean to launch Piedmont’s first heart transplant program.
Dr. David Kandzari to lead national clinical trials from Atlanta base.
ATLANTA, Ga (August 19, 2010) – With a vision to deliver the highest standards in cardiovascular care, Piedmont Heart Institute (PHI) welcomes two experts in the field of cardiovascular medicine this month -- David Dean, M.D., cardiothoracic, heart transplant and ventricular assist device surgeon as well as a nationally recognized thought leader and researcher; and David Kandzari, M.D., internationally renowned clinical interventional cardiologist and researcher. As leaders in cardiovascular surgery and medicine, Doctors Dean and Kandzari will continue to draw the national spotlight to PHI as a recognized destination for cardiovascular excellence in the Southeast.
Piedmont Heart Institute is a cardiovascular care program headquartered at Piedmont Hospital, which was the recipient of a 2010 HealthGrades® award for Best in Atlanta for Overall Cardiac Care, Cardiac Surgery and Coronary Intervention. Piedmont Heart Institute also receives top patient satisfaction scores, averaging in the 87th percentile for the first four months of 2010.
“The addition of Doctors Dean and Kandzari signifies a critical milestone in our vision – moving from a tertiary to a quaternary cardiovascular care center,” said William D. Knopf, M.D., chief operating officer of Piedmont Heart Institute and vice president of Cardiovascular Services at Piedmont Hospital. “Combined with our existing clinical capabilities and research program, the addition of these exemplary physicians creates an unparalleled level of quality in the metro Atlanta market.”
David Dean, M.D.
Joining Piedmont Heart Institute from Allegheny General Hospital in Pittsburgh, Pa., Dr. Dean will launch PHI’s heart transplant program. The addition of this acclaimed transplant surgeon, who sits on the heart review board of the Organ Procurement and Transplantation Network/ United Network for Organ Sharing, moves PHI from a tertiary cardiac care provider to a quaternary one.
There are only three other hospitals in Georgia which perform heart transplants, and no others that have a physician primarily devoted to adult heart transplantation, as Dr. Dean will be. The start of heart transplant expands on the services currently being offered through the Piedmont Hospital Transplant Institute, which includes kidney, pancreas and liver transplantation. This foundation in transplant enables Piedmont physicians to draw upon their overall transplant experience to deliver best-in-class care.
Dr. Dean is passionate about the use of new cardiovascular technologies to prolong life and has gained national recognition for his research. A principle investigator and prominent expert in the area of ventricular assist devices, which allow a pump to assist and augment a failing heart, Dr. Dean is able to sustain the life of those patients who are awaiting heart transplants, as well as those who are not deemed candidates for heart transplant. With Dr. Dean’s arrival, patients will gain further access to advanced technology in ventricular assist devices and be able to have these procedures at Piedmont Healthcare’s flagship cardiovascular center, the Fuqua Heart Center of Atlanta at Piedmont Hospital.
David Kandzari, M.D.
Dr. Kandzari has achieved international recognition for his work in the field of interventional cardiology. A former professor at Duke University’s Cardiovascular Research Institute and former chief medical officer at Johnson & Johnson’s Cordis Corporation, Dr. Kandzari is also an ad hoc medical reviewer to the FDA and committee member on the FDA Circulatory Systems Devices Panel. As a national principal investigator for a number of multi-center cardiovascular trials, Dr. Kandzari has been responsible for leading numerous studies related to drug-eluting stents, antithrombotic therapies and additional novel therapies in both coronary and peripheral artery disease. His highly-regarded work puts him at the forefront of designing and shepherding new treatments and technologies, which he will bring to the patients served by PHI.
In his role, Dr. Kandzari will split his focus equally between clinical patient care and developing and leading a robust national research program. His tremendous research experience and his world-renowned expertise opens the way for PHI to take a leading role in current and future clinical trials – even expanding beyond cardiovascular care and treatment.